mRNA cancer vaccine prevents melanoma recurrence
A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
The results, announced this week by Moderna and Merck, could pave the way for a new generation of treatments tailored to individual tumors
A personalized cancer vaccine, used in combination with an existing treatment, helped prevent the return and spread of melanoma in a late-stage clinical trial, Moderna and Merck, the companies developing the drug, announced this week. The results bring the vaccine, called intismeran, one step closer to regulatory approval and potentially wider use.
Read more at Smithsonian Magazine